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Background: Atrial fibrillation (AF) is associated with adverse outcomes in terms of survival and
morbidity. Peripheral artery disease (PAD) and AF share several common risk factors and often
coexist. Whether AF has a prognostic role in patients with PAD has not been extensively
studied.
Hypothesis: AF is associated with major adverse cardiac events (MACE) and mortality in symp-
tomatic PAD patients.
Methods: Using MEDLINE and Scopus, we searched for studies published before December
2016 that evaluated cardiovascular outcomes based on the presence/absence of AF in a pro-
spective manner with a follow-up period of ≥12 months. The outcomes were reported using a
random-effects model, and heterogeneity was assessed using the I2 statistic. Sensitivity ana-
lyses were performed to test the contribution of each study to the overall results.
Results: Six prospective studies (Newcastle-Ottawa score range, 7–9) with 14 656 patients
were included in the final analysis (age range, 66–70 years; median follow-up, 1.4 years). Our
pooled analysis found a significant association between AF and mortality (odds ratio: 2.52, 95%
confidence interval: 1.91-3.34, I2 = 32.6%), without evidence of publication bias (P = 0.63).
Meta-analysis showed a significant impact of AF on MACE (odds ratio: 2.54, 95% confidence
interval: 1.78-3.63, I2 = 74.3%), without detected publication bias (P = 0.08).
Conclusions: AF is associated with increased risk of mortality and MACE in symptomatic PAD.
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1 | INTRODUCTION
Atrial fibrillation (AF) and peripheral artery disease (PAD) are quite
prevalent in the aging population and often coexist.1 They share
many common risk factors, including hypertension (HTN), diabetes
mellitus (DM) and obesity, and are both associated with increased
cardiovascular (CV) mortality and ischemic CV events.1 Vascular dis-
ease was found to increase the risk of AF and complications associ-
ated with AF.2 Recently, vascular disease (including myocardial
infarction [MI], aortic plaque, and PAD) was included in the
CHA2DS2-VASc (congestive heart failure, HTN, age ≥ 75 years, DM,
prior stroke, vascular disease, age 65–74 years, sex category) risk
score, thus underlining the importance of PAD as a prognostic factor
in patients with AF.3
Although systematic reviews and meta-analyses undoubtedly
showed the association of AF with increased risk of mortality in patients
with coronary artery disease (CAD),4,5 the prognostic implication of AF in
PAD was not extensively studied. Therefore, we performed a compre-
hensive systematic review and meta-analysis of available studies to
assess the prognostic effect of AF to predict risk of major adverse cardio-
vascular events (MACE) and mortality in patients with symptomatic PAD.
2 | METHODS
2.1 | Search strategy
During the conduct of this meta-analysis, we followed Meta-Analysis
of Observational Studies in Epidemiology (MOOSE) guidelines.6 We
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performed a systematic literature search of MEDLINE and Scopus for
all studies published between January 1993 and December 2016
without language restriction, using the following medical subject
headings: “atrial fibrillation,” “peripheral artery disease,” “peripheral
vascular disease,” “critical limb ischemia,” “cardiovascular outcome,”
and “mortality.” Additional studies were identified by manual search
of references of original studies or review studies.
2.2 | Study inclusion and outcomes
We included prospective cohort studies that evaluated the prognostic
impact of AF on all-cause mortality and/or MACE (composite end-
point of MI, stroke, and death) in patients with symptomatic PAD
(intermittent claudication and/or critical limb ischemia [CLI]) with a
follow-up period of ≥12 months. All patients were categorized based
on the presence or absence of AF (electrocardiographic evidence of
arrhythmia) at the time of enrollment, and clinical outcomes of AF
patients were compared with non-AF patients.
2.3 | Data extraction and quality assessment
Study selection and data extraction were conducted independently
by 2 investigators (MV, AVP). Any disagreements or differences in
the data extraction between the 2 authors were harmonized by con-
sensus after rechecking the source data. Study quality was assessed
using the validated Newcastle-Ottawa Scale for assessment of non-
randomized and observational studies, and studies were evaluated
based on subject selection, comparability of study groups, and assess-
ment of the outcome.7 Completed database contained the following
data: name of the first author; year of publication; country of origin;
study design; total number of patients in each study; the number of
patients with AF; the proportion of patients with HTN, DM, CAD,
and CLI; medical treatment (ie, the use of anticoagulants, antiplatelet
drugs, statins, and angiotensin-converting enzyme inhibitors [ACEIs]
or angiotensin II receptor blockers [ARBs]); the percentage of patients
who died and experienced MACE in each group (with and without
AF); the follow-up period; conduction of multivariate analysis; and
confounding factors. The studies included symptomatic PAD patients
suffering from CLI together with patients with intermittent claudica-
tion. One study reported the values of ankle-brachial index.8
2.4 | Statistical analysis
Meta-analysis of outcome was reported using a random-effects
model, and pooled odds ratio (OR) was reported with 95% confidence
interval (CI). Statistical heterogeneity was assessed using the
Cochrane Q test and I2 statistic. Statistically significant heterogeneity
was considered present at P < 0.10 and I2 > 50%. The Begg and
Mazumdar rank correlation test was used to assess the risk for publi-
cation bias. Sensitivity analyses were performed by excluding trials
1 at a time to test the contribution of each study to the pooled esti-
mates. Analyses were conducted using statistical software StatsDirect
version 3.0.165 (StatsDirect Ltd., England, United Kingdom).
3 | RESULTS
3.1 | Selected studies and baseline characteristics
A total of 54 citations were obtained from electronic search. After reading
titles and abstracts, followed by review of potentially relevant studies,
6 prospective studies were included in final analysis,8–13 including a total
of 14 656 patients (Figure 1). A median follow-up period was 1.4 years
(range, 1.0–2.0 years). The study characteristics are listed in Table 1. The
mean age of the population was 68 years (range, 66–70 years); 69%
(range, 59%–85%) were males; 71% (range, 36%–87%) had HTN; 48%
(range, 21%–59%) had CAD; and 42% (range, 31%–54%) had DM. Three
studies9,12,13 reported the prevalence of patients with CLI, which on aver-
age was 22% (range, 18%–42%). The average prevalence of AF among
PAD patients was 11.4% (range, 8.0%–17.9%). CHADS2 (congestive heart
failure, HTN, age > 75 years, DM, stroke) scores differed between groups
with and without AF (2.51 vs 2.01, respectively). Both groups were com-
parable in the use of statins (73% vs 77%) and ACEIs/ARBs (75% vs 70%),
with more frequent use of anticoagulants (55% vs 8%) and less frequent
use of antiplatelet drugs (58% vs 87%) in the AF group (Table 1). The com-
bined use of anticoagulants and antiplatelet medications in patients with
AF was reported in 3 studies9,11,12 and was on average 16% (range, 8%–
30%). Multivariate statistical analysis was performed in 5 studies.8–11,13
Three studies reported the cause of death,9,11,13 and CV death comprised
62% (range, 52%–67%). Using the Newcastle-Ottawa scoring system, the
median score for included studies was 8 (range, 7–9).
3.2 | Quantitative data synthesis
In pooled analysis, there was a significant association between AF
and mortality (OR: 2.52, 95% CI: 1.91-3.34; Figure 2A). The analysis
of pooled studies showed a low to moderate heterogeneity
(I2 = 32.6%, Cochran Q = 5.93, P = 0.20), without evidence of publi-
cation bias (P = 0.63). None of the studies had a significant impact on
the overall OR or the statistical significance (Table 2).
Meta-analysis of studies that reported MACEs showed a signifi-
cant impact of AF on CV outcomes (OR: 2.54, 95% CI: 1.78-3.63;
Figure 2B). Significant heterogeneity was observed across the studies
(I2 = 74.3%, Cochran Q = 15.58, P = 0.004), without detected publi-
cation bias (P = 0.08).
FIGURE 1 Study flow diagram for meta-analysis of AF and PAD
outcomes. Abbreviations: AF, atrial fibrillation; PAD, peripheral artery
disease
1232 VRSALOVIĆ AND PRESEcKI
4 | DISCUSSION
The prognostic role of AF, although well established in ischemic heart
disease, was not comprehensively examined in PAD patients. Accord-
ing to our meta-analysis, the coexistence of PAD and AF identified
high-risk patients for MACE and mortality.
PAD is a marker of advanced atherosclerotic disease.14,15 Because
involvement of multiple vascular territories (and frequently associated
CAD) is often present in PAD patients, these patients have an
increased risk for CV ischemic events and CV death.16 They represent
a population at high CV risk that is comparable to individuals with pre-
vious MI, coronary revascularization, and other arterial revasculariza-
tion procedures.14 Consequently, current guidelines recommend that
PAD patients receive optimal medical treatment (ie, antiplatelet ther-
apy and lipid-lowering agents [statins]), together with smoking cessa-
tion and ACEIs, as they substantially reduce the likelihood of adverse
CV outcomes.14 At the same time, according to guidelines, patients
with AF and stable vascular disease (arbitrarily defined as being free
from any acute ischemic event or repeat revascularization for >1 year)
should be managed with oral anticoagulants alone, without antiplatelet
therapy.17 In our meta-analysis, both groups of patients were compara-
ble in the use of statins and ACEI/ARBs. Less frequent use of antiplate-
let drugs was reported in the AF group of patients (58% vs 87%), 55%
of AF patients received anticoagulation treatment, and the combined
use of anticoagulants and antiplatelet medications averaged at 16%.
Thus, the above-mentioned treatment differences could be, at least in
part, responsible for the increased CV risk in PAD patients with AF.
On the other hand, AF itself is associated with elevated inflam-
matory biomarkers (C-reactive protein and interleukin-6), together
with increased platelet activation, thrombin generation, and endothe-
lial dysfunction.18–20 So, it is plausible that AF in a patient with PAD
predisposes them to a pro-inflammatory and prothrombotic state that
may promote plaque destabilization and plaque rupture with conse-
quent unfavorable CV events.
In line with our meta-analysis, AF was associated with almost a
doubling in mortality in subjects from the original cohort of the Fra-
mingham Heart Study, even after adjustment for the preexisting CV
conditions that were related to AF.21 Moreover, the recently pub-
lished meta-analysis revealed that AF was associated with a 71%
increased risk of MI in patients free of CAD at baseline.22
AF and PAD share several common CV risk factors, including age,
HTN, DM, and obesity.1,2 Our analysis showed that CHADS2 scores
differed between groups with and without AF, suggesting a population
at higher risk for ischemic events. So, the increased risk for CV events
may be attributed to the comorbidities together with inflammation
and increased prothrombotic activity associated with AF. Therefore,
more attention should be paid to patients in whom coexistence of AF
and PAD occurs, as they represent a vulnerable subgroup at a very
high risk for adverse outcomes. In this way, AF in patients with PAD
may serve as a surrogate marker of more severe disease with subse-
quent poor CV outcomes in terms of survival and morbidity.
The results of our systematic review and meta-analysis, which
included high-quality prospective cohort studies, for the first time clearly
showed the increased risk of all-cause mortality rates and MACE in
patients with coexisting AF and symptomatic PAD. These findings are inT
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line with previously published meta-analyses on the prognostic role of
AF in CAD.4,5,22 As warfarin and other vitamin K antagonists are known
to increase vascular calcification and calcification of coronary arteries,
future trials are needed to evaluate the potential benefit of direct oral
anticoagulants in patients with atherosclerotic vascular disease and AF.23
Further prospective studies are needed to evaluate the prognos-
tic role of AF in the whole spectrum of symptomatic and asymptom-
atic patients with peripheral vascular disease.
4.1 | Study limitations
Only patients who had symptomatic PAD of the lower extremities
were included; therefore, asymptomatic patients and those with PAD
of arteries other than lower-limb arteries were not evaluated in this
systematic review.
Characteristics of patients with and without AF may very well differ,
and thus the effect of AF may be confounded by other comorbidities.
FIGURE 2 Meta-analysis (random-effects
model) testing the prognostic impact of AF
on (A) all-cause mortality and (B) MACE in
patients with symptomatic PAD.
Abbreviations: AF, atrial fibrillation; MACE,
major adverse cardiac events; PAD,
peripheral artery disease
TABLE 2 Sensitivity analyses excluding 1 study at a time
Author, Year
MACE Mortality
OR 95% CI I2, % OR 95% CI I2, %
Aguilar, 2012 2.44 1.61-3.69 77.1 2.50 1.77-3.55 47.1
Conway, 2004 — — — 2.54 1.81-3.56 48.9
Goto, 2008 2.86 2.22-3.69 21.7 2.97 2.24-3.94 0
Sanclemente, 2014 2.44 1.61-3.67 77.5 2.54 1.76-3.66 48.4
Vrsalovic, 2016 2.30 1.61-3.28 72.3 — — —
Winkel, 2010 2.69 1.64-4.42 80.7 2.21 1.73-2.83 0
Abbreviations: CI, confidence interval; MACE, major adverse cardiovascular events; OR, odds ratio.
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The various types of AF (paroxysmal, persistent, permanent)
were not differentiated in the included studies. The effect of AF type
on CV outcomes in PAD patients needs further evaluation in future
prospective clinical trials. The information about patients with asymp-
tomatic episodes of AF or patients who may have developed AF dur-
ing follow-up does not exist in the studies included in the meta-
analysis.
5 | CONCLUSION
The results of this systematic review and meta-analysis showed that
AF is associated with an increased risk of mortality and MACE in
patients with symptomatic peripheral vascular disease.
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